Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.70 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18523466 | 0.93 | CYP19A1 (0.61) | CYP19A1TLR2TLR1MAPTALDH1A1 | |
| SCHEMBL17199051 | 0.85 | CYP19A1 (0.75) | CYP19A1MAPTALDH1A1PTGS1PKM | |
| SCHEMBL17199149 | 0.84 | CYP19A1 (0.49) | CYP19A1TLR2TLR1MAPTKIF11 | |
| SCHEMBL17199054 | 0.83 | CYP19A1 (0.75) | CYP19A1MAPTALDH1A1PTGS2PKM | |
| SCHEMBL17199247 | 0.83 | CYP19A1 (0.48) | CYP19A1TLR2TLR1 | |
| SCHEMBL2420496 | 0.82 | CYP19A1 (1.00) | CYP19A1MAPTALDH1A1PKMRAB9A | |
| SCHEMBL18470539 | 0.78 | KMT2A (0.42) | CYP19A1MAPTKIF11PTGESRAB9A | |
| SCHEMBL16862008 | 0.77 | KCNH2 (0.48) | CYP19A1MAPTALDH1A1KIF11PTGS2 | |
| SCHEMBL17199121 | 0.77 | KIF11 (0.47) | CYP19A1KIF11PTGESRAB9A | |
| SCHEMBL28221330 | 0.76 | PTGES (0.39) | CYP19A1MAPTKIF11PTGESRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3133068-B1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF | Shanghai hengrui pharmaceutical co ltd (CN) | 2020-11-25 | — | — | EP | disclosed |
| US-10081629-B2 | Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-09-25 | — | — | US | disclosed |
| CN-105636951-B | Amide derivatives and its officinal salt, its preparation method and its application in medicine | 上海恒瑞医药有限公司 | 2018-05-15 | — | — | CN | disclosed |
| EP-3133068-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2017-02-22 | — | — | EP | disclosed |
| EP-3133068-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2017-02-22 | — | — | EP | disclosed |
| US-20170037044-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND MEDICINAL APPLICATION THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
| US-20170037044-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND MEDICINAL APPLICATION THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
| US-20170037044-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND MEDICINAL APPLICATION THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
| CN-105636951-A | Amide derivatives and pharmaceutically acceptable salts thereof, preparation method and medical application thereof | Shanghai hengrui pharmaceutical co ltd | 2016-06-01 | — | — | CN | disclosed |
| WO-2015158204-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF | 上海恒瑞医药有限公司 | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10081629-B2 | Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof | PTGES, PTGS1, PTGIS | CYP19A1 276/4885TLR2 1309/4885TLR1 663/4885 |
| US-20170037044-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND MEDICINAL APPLICATION THEREOF | PTGES, PTGS1, PTGIS | CYP19A1 276/4885TLR2 1309/4885TLR1 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.